NOT FOR DISTRIBUTION
Header cover image

Eurobio Scientific Société anonyme

Market Cap

€208.2m

Last Updated

2021/05/15 19:17 UTC

Data Sources

Company Financials +

Executive Summary

Eurobio Scientific Société anonyme discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. More Details


Snowflake Analysis

Undervalued with solid track record.

Share Price & News

How has Eurobio Scientific Société anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALERS is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ALERS's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

0.4%

ALERS

-2.6%

FR Biotechs

-0.2%

FR Market


1 Year Return

77.8%

ALERS

35.7%

FR Biotechs

48.4%

FR Market

Return vs Industry: ALERS exceeded the French Biotechs industry which returned 35.7% over the past year.

Return vs Market: ALERS exceeded the French Market which returned 48.4% over the past year.


Shareholder returns

ALERSIndustryMarket
7 Day0.4%-2.6%-0.2%
30 Day-18.7%-6.0%2.6%
90 Day-11.5%-16.8%11.0%
1 Year77.8%77.8%35.7%35.7%52.3%48.4%
3 Year297.9%297.9%-19.8%-19.8%26.2%15.3%
5 Year126.6%126.6%-48.1%-48.2%78.4%55.3%

Long-Term Price Volatility Vs. Market

How volatile is Eurobio Scientific Société anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eurobio Scientific Société anonyme undervalued compared to its fair value and its price relative to the market?

31.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALERS (€18.58) is trading below our estimate of fair value (€27.1)

Significantly Below Fair Value: ALERS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALERS is good value based on its PE Ratio (2.9x) compared to the European Biotechs industry average (31.5x).

PE vs Market: ALERS is good value based on its PE Ratio (2.9x) compared to the French market (24.5x).


Price to Earnings Growth Ratio

PEG Ratio: ALERS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ALERS is good value based on its PB Ratio (1.9x) compared to the FR Biotechs industry average (4.3x).


Future Growth

How is Eurobio Scientific Société anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-79.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALERS's earnings are forecast to decline over the next 3 years (-79.2% per year).

Earnings vs Market: ALERS's earnings are forecast to decline over the next 3 years (-79.2% per year).

High Growth Earnings: ALERS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ALERS's revenue is expected to decline over the next 3 years (-5.8% per year).

High Growth Revenue: ALERS's revenue is forecast to decline over the next 3 years (-5.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALERS's Return on Equity is forecast to be low in 3 years time (13.3%).


Past Performance

How has Eurobio Scientific Société anonyme performed over the past 5 years?

78.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALERS has a high level of non-cash earnings.

Growing Profit Margin: ALERS's current net profit margins (38.8%) are higher than last year (5.5%).


Past Earnings Growth Analysis

Earnings Trend: ALERS has become profitable over the past 5 years, growing earnings by 78.8% per year.

Accelerating Growth: ALERS's earnings growth over the past year (2132%) exceeds its 5-year average (78.8% per year).

Earnings vs Industry: ALERS earnings growth over the past year (2132%) exceeded the Biotechs industry 21.8%.


Return on Equity

High ROE: ALERS's Return on Equity (68.1%) is considered outstanding.


Financial Health

How is Eurobio Scientific Société anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: ALERS's short term assets (€135.2M) exceed its short term liabilities (€48.0M).

Long Term Liabilities: ALERS's short term assets (€135.2M) exceed its long term liabilities (€16.5M).


Debt to Equity History and Analysis

Debt Level: ALERS's debt to equity ratio (23.1%) is considered satisfactory.

Reducing Debt: ALERS's debt to equity ratio has increased from 3.9% to 23.1% over the past 5 years.

Debt Coverage: ALERS's debt is well covered by operating cash flow (220.5%).

Interest Coverage: ALERS's interest payments on its debt are well covered by EBIT (134.9x coverage).


Balance Sheet


Dividend

What is Eurobio Scientific Société anonyme current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALERS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALERS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALERS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALERS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALERS's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Jean-Michel Grandmougin

3.92yrs

Tenure

Mr. Jean-Michel Carle Grandmougin is President of the Management Board at at Eurobio Scientific Société anonyme (also known as Diaxonhit) since June 2017. As President of DIAXONHIT's Management Board since...


Leadership Team

Experienced Management: ALERS's management team is seasoned and experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Eurobio Scientific Société anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eurobio Scientific Société anonyme
  • Ticker: ALERS
  • Exchange: ENXTPA
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €208.229m
  • Shares outstanding: 11.21m
  • Website: https://www.diaxonhit.com

Number of Employees


Location

  • Eurobio Scientific Société anonyme
  • 7 avenue de Scandinavie
  • ZA de Courtaboeuf
  • Les Ulis
  • Ile-de-France
  • 91953
  • France

Listings


Biography

Eurobio Scientific Société anonyme discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quic...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 19:17
End of Day Share Price2021/05/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.